NCT01334723 - Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia | Biotech Hunter

Enrollment

35,032

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

June 30, 2010

Conditions

Prostatic Hyperplasia

Interventions

DRUG

Adherent with 5-alpha-reductase inhibitor (5ARI) therapy

Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)

DRUG

Non-adherent to 5ARI therapy

Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)